A Multicentre, Randomised, Double-Blind, Double-Dummy, Parallel-Controlled, Phase 3 Clinical Trial Assessing the Efficacy and Safety of Intravenous Nemonoxacin Malate Versus Levofloxacin for Community-Acquired Pneumonia in Adult Patients
Ying Li,Demei Zhu,Shenghua Sun,Xiaoyue Chang,Zhaolong Cao,Yanping Yang,Xiuhua Fu,Xiangyang Li,Jinfu Xu,Yingqun Zhu,Fuxin Hui,Xingxiang Xu,Zhang Chen,Liping Peng,Zhuang Ma,Biwen Mo,Chen Li,Yuan Lv,Li Zhao,Guangfa Zhu,Yong He,Hua Liu,Jichao Chen,Ying Wang,Yongjie Liang,Youjin Lu,Zhiqiang Qin,Hongzhong Yang,Min Zhang,Shiman Wu,Zhaohui Tong,Feng Ye,Zuke Xiao,Xuefen Wang,Chen Qiu,Jiulong Kuang,Huaping Huang,Kai Wang,Kejing Ying,Faguang Jin,Xiaoju Lv,Yijiang Huang,Deling Liu,Wei Wang,Yingyuan Zhang
DOI: https://doi.org/10.1016/j.ijantimicag.2024.107235
IF: 15.441
2024-01-01
International Journal of Antimicrobial Agents
Abstract:Background: Nemonoxacin malate is a novel non-fluorinated quinolone for oral and intravenous (IV) administration. This phase 3, multicentre, randomised, double-blind, double-dummy, parallel-controlled clinical trial (NCT02205112) evaluated the efficacy and safety of IV nemonoxacin vs. levofloxacin for the treatment of community-acquired pneumonia (CAP) in adult patients. Methods: Eligible patients were randomised to receive 500 mg nemonoxacin or levofloxacin via IV infusion, once daily for 7-14 days. The primary endpoint was the clinical cure rate at the test-of-cure (TOC) visit in the modified intent-to-treat (mITT) population. Secondary efficacy and safety were also compared between nemonoxacin and levofloxacin. Results: Overall, 525 patients were randomised and treated with nemonoxacin ( n = 349) or levofloxacin ( n = 176). The clinical cure rate was 91.8% (279/304) for nemonoxacin and 85.7% (138/161) for levofloxacin in the mITT population ( P > 0.05). The clinical efficacy of nemonoxacin was non-inferior to levofloxacin for treatment of CAP. Microbiological success rate with nemonoxacin was 88.8% (95/107) and with levofloxacin was 87.8% (43/49) ( P > 0.05) at the TOC visit in the bacteriological mITT population. The incidence of drug-related adverse events (AEs) was 37.1% in the nemonoxacin group and 22.2% in the levofloxacin group. These AEs were mostly local reactions at the infusion site, nausea, elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST), and QT interval prolongation. The nemonoxacinrelated AEs were mostly mild and resolved after discontinuation of nemonoxacin. Conclusions: Nemonoxacin 500 mg IV once daily for 7-14 days is effective and safe and non-inferior to levofloxacin for treating CAP in adult patients. (c) 2024 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )